Mice deficient of Lats1 develop soft-tissue sarcomas, ovarian tumours and pituitary dysfunction

Maie A R St John,Wufan Tao,Xiaolan Fei,Royd Fukumoto,Maria Luisa Carcangiu,David G Brownstein,Albert F Parlow,James McGrath,Tian Xu
DOI: https://doi.org/10.1038/5965
IF: 30.8
1999-01-01
Nature Genetics
Abstract:The lats gene has been identified as a tumour suppressor in Drosophila melanogaster using mosaic screens 1 . Mosaic flies carrying somatic cells that are mutant for lats develop large tumours in many organs 1 , 2 . The human LATS1 homologue rescues embryonic lethality and inhibits tumour growth in lats mutant flies, demonstrating the functional conservation of this gene 3 . Biochemical and genetic analyses have revealed that LATS1 functions as a negative regulator of CDC2 ( ref. 3 ). These data suggest that mammalian LATS1 may have a role in tumorigenesis. To elucidate the function of mammalian LATS1 , we have generated Lats1 –/– mice. Lats1 –/– animals exhibit a lack of mammary gland development, infertility and growth retardation. Accompanying these defects are hyperplastic changes in the pituitary and decreased serum hormone levels. The reproductive hormone defects of Lats1 –/– mice are reminiscent of isolated LH–hypogonadotropic hypogonadism and corpus luteum insufficiency in humans. Furthermore, Lats1 –/– mice develop soft–tissue sarcomas and ovarian stromal cell tumours and are highly sensitive to carcinogenic treatments. Our data demonstrate a role for Lats1 in mammalian tumorigenesis and specific endocrine dysfunction.
What problem does this paper attempt to address?